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eMidterm Results of Percutaneous Treatment for Acute and Chronic
Deep Venous Thrombosis
Gregory A. Stanley, Erin H. Murphy, Mitchell M. Plummer, Jayer Chung,
J. Gregory Modrall, Frank R. Arko, III, UT Southwestern, Dallas, Tex
Background:Traditional treatment of deep venous thrombosis (DVT)
with therapeutic anticoagulation has been increasingly challenged by aggres-
sive percutaneous treatment using ultrasound-accelerated catheter directed
thrombolysis (US-CDT) or percutaneous pharmacomechanical thrombec-
tomy (PMT). These techniques have been promoted to improve thrombus
removal, prolong venous patency, prevent venous insufficiency, and reduce
postthrombotic syndrome. This study reviews midterm results using these
endovascular techniques for both acute and chronic DVT.
Methods: A retrospective chart review was performed on patients
treated for acute or chronic DVT with US-CDT and/or PMT. Charts were
reviewed for patient demographics, symptoms and time course of venous
thrombosis, anticoagulation regimen, underlying prothrombotic disorders,
operative details, and postoperative outcomes. Intraoperative venography
and intravascular ultrasound (IVUS) quantified clot response to therapy.
Duplex ultrasound defined the pre- and postoperative extent of venous
thrombosis, venous patency, and valvular function.
Results: Between October 1, 2002 and September 30, 2010, eighty-
seven patients were treated for iliofemoral (n  48), iliofemoropopliteal
(n  15), femoropopliteal (n  17), or subclavian (n  7) venous throm-
bosis. Mean age was 45.8 years (range, 15-78 years) and 27 patients (31%)
had a documented history of hypercoaguable state. IVUS confirmed May-
Thurner syndrome in 34 patients (39%). Fifty-nine patients (68%) were
treated for acute symptoms; the mean time to intervention from symptom
onset was 7.0 days (range, 1-14 days). The remaining 28 patients (32%) had
severe chronic symptoms and were treated at a mean of 8.6 months (range,
1.5-36 months) after DVT diagnosis was made. Patients were treated with
PMT (n  52, 58%), US-CDT (n  14, 16%), or both (n  22, 25%).
Adjunctive procedures, including percutaneous transluminal angioplasty
alone or with stent placement, were required in 59% (n  35) of acute
patients and in 96% (n  27) of chronic patients (P .09). A significant
decrease in clot burden (50%) or complete clot lysis was achieved in 79 of
87 patients (91%). Three patients (3.4%) had postoperative bleeding events
requiring blood transfusion; there were no occurrences of intracranial hem-
orrhage or clinically significant pulmonary embolism. At amean follow-up of
3.8 years (range, 1-8.9 years), venous patency was present in 55 of 59 acute
patients (93%) and in 23 of 28 chronic patients (82%)( P  .14). However,
of the 80 lower extremities treated, valve function was preserved in 41 of 52
(79%) acute patients versus only 11 of 28 (39%) chronic patients (P .001).
Conclusions: Ultrasound-accelerated thrombolysis or percutaneous
mechanical thrombectomy used alone or in tandem for treatment of acute
and chronic deep venous thrombosis improves symptoms in the involved
limb and maintains venous patency at midterm follow-up. Valvular function
in the lower extremity is better preserved when sufficient treatment is
provided acutely after the onset of symptoms. However, a beneficial symp-
tomatic response is achievable in patients with chronic deep venous throm-
bosis or post phlebitis syndrome and should be considered in this popula-
tion.
Endovascular Management of Acute Symptomatic Inferior Vena Cava
Thombosis: Efficacy and Outcomes
Charles C. Sticco, Jonathan A. Schor, Kuldeep Singh, Quinghua Pu,
Jonathan S. Deitch, Staten Island University Hospital, Staten Island, NY
Introduction: The management of acute caval thrombosis (ACT) has
evolved to catheter-based therapies the results of which remain uncertain.
We report our 7 year experience treating acute inferior vena cava (IVC)
thrombosis using endovascular methods.
Methods: Demographic, clinical, procedural and outcome data was
prospectively collected for symptomatic patients presenting with IVC
thrombosis between the years 2004-2011. Multimodality treatment using
catheter directed thrombolysis (CDT) with tissue plasminogen activator
(t-PA), pharmacomechanical catheter-directed thromboylysis (PCDT),
venoplasty and venous stenting was used.
Results: Seventeen patients (59% male) underwent treatment for acute
( 2 weeks) symptomatic inferior vena cava thrombosis. Presenting symp-
toms were limb swelling in 16 patients (94%), pain in 15 patients (88%),
motor dysfunction in 9 patients (53%) and sensory loss in 6 patients (35%).
Phlegmasia cerulean dolens was present in 7 patients. A history of malig-
nancy was identified in six. Five patients had a prior history of DVT and were
being treating with warfarin with subtherapeutic international normalized
ratios (INR). Fourteen of the patients had an inferior vena cava filter at
presentation (Trapease 8, G2X 3, Option 2, Eclipse 1). Two patients had a
documented hypercoaguable state. Twelve patients underwent venous an-
gioplasty. Four patients (24%) underwent venous stenting of the IVC or
iliofemoral position. Mean tissue plasminogen activator (t-PA) intraopera-
tive dose was 21.5 mg. Mean t-PA infusion dose was 10.3mg. 53% of
patients required two interventions and none required more than three
interventions. Significant (50% luminal gain) angiographic resolution ofenous thrombus was achieved in 88% of patients. Symptomatic improve-
ent was observed in 94% of patients. Two patients who presented with
hlegmasia died following intervention. Three patients (18%) had clinically
ymptomatic pulmonary embolism. One patient underwent an above knee
mputation secondary to venous gangrene. Other complications included
ocal hematoma (18%) and hematuria (71%), all of which resolved sponta-
eously. There were no observed episodes of major bleeding complications.
here were no remote bleeding complications. 11 (65%) patients were
onitored with venous duplex and clinical exam. Median follow up was 12
onths (range, 2-21 months). 8 (72%) remained patent on duplex. Symp-
omatic improvement was noted in 82% with complete resolution of symp-
oms in 64%. Late complications including pain, swelling and venous ulcer-
tion were noted in 36%.
Conclusions: Endovascular treatment of ACT, regardless of etiology,
s a safe and effective with good short term clinical results even in patients
ho rethrombosed. An aggressive endovascular approach to treatment of
cute symptomatic ACT is warranted even in the presence of a thrombosed
aval filter. The presence of phlegmasia portends a poor prognosis.
atheter-Directed Thrombolytic Therapy for Massive and Submassive
ulmonary Embolus: A Community Hospital Experience
effrey Y.Wang, Shan-ali Haider, Richard Silva,Michael Sulkin, Robert Fox,
hady Grove Adventist Hospital, Rockville, Md
Introduction: Pulmonary embolism (PE) is responsible for 200,000
eaths in theUnited States annually. Catheter directed thrombolytic therapy
CDTT) is reserved for massive and submassive PE, and rarely practiced
utside of tertiary care university settings. Here we present a series of nine
onsecutive patients with massive (on pressors with hemodynamic instabil-
ty) or submassive PE (echocardiograms showing pulmonary artery pressure
70 mm Hg, right heart strain, and continued need for supplemental
xygen ) treated with CDTT in a community vascular surgery practice.
Methods: Four patients were treated for massive PE and five were
reated for submassive PE. All patients had been treated in intensive care
nits with systemic anticoagulation and significant supplemental oxygen
equirement for as long as 5 days prior to being referred for lytic therapy.
pon referral, patients were treated with CDTTwith powerpulse infusion of
0 to 15 mg of Alteplase into the left, right, and main pulmonary arteries.
he decision to use mechanical thrombectomy was made at the time of
rocedure based on the patient’s clinical condition.
Results:All nine patients were treated in a single setting. Themean age
as 54.8  11.4 years, with 1 male and 8 females. The end point of
reatment was weaning off pressors and/or decreased oxygen requirement.
his was achieved in all nine patients (100% procedural success rate). One
atient developed hemodynamically significant heart block with each at-
empt at powerpulse delivery, but was successfully treated with forceful
njection through a running EKOS catheter. All patients were off supple-
ental oxygen within 24 hours of the procedure. There were no bleeding
vents in any patient. One patient expired 14 hours after the procedure withFig.
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